Marginal Jawbone Loss Is Associated With the Onset of Rheumatoid Arthritis and Is Related to the Plasma Level of RANKL
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 22, 2018 Category: Rheumatology Authors: Paola Pablo Tags: Editorial Source Type: research
Vasudhaiva Kutumbakam The World is One Family
This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 22, 2018 Category: Rheumatology Authors: Sharad Lakhanpal Tags: Special Source Type: research
What can our hands tell us about the future of our knees?
This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 22, 2018 Category: Rheumatology Authors: Jamie E. Collins Tags: Editorial Source Type: research
Association of Quantitative and Topographic Assessment of Heberden's Nodes with Knee Osteoarthritis: Data from Osteoarthritis Initiative
ConclusionHN number, their locations, and symmetry were associated with knee OA incidence and progression over 8‐years.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 22, 2018 Category: Rheumatology Authors: Neil Kumar, Nima Hafezi ‐Nejad, Ali Guermazi, Arya Haj‐Mirzaian, Ida K. Haugen, Frank W. Roemer, Shadpour Demehri Tags: Brief Report Source Type: research
Clinical evolution of patients with new ‐onset inflammatory back pain: a population‐based cohort study
ConclusionA minority of patients with new‐onset IBP progress to SpA, while many resolve. That IBP often resolves may explain the difference between the prevalence of IBP (3‐6%) and prevalence of SpA (0.5‐1%).This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 22, 2018 Category: Rheumatology Authors: Runsheng Wang, Cynthia S. Crowson, Kerry Wright, Michael M. Ward Tags: Full Length Source Type: research
Attenuated effectiveness of tumor necrosis factor inhibitors for anti ‐human T‐lymphotropic virus type 1 antibody‐positive rheumatoid arthritis
ConclusionsThe efficacy of TNF inhibitors may be attenuated in RA patients with positive anti‐HTLV‐I antibody. ATL and HAM did not develop when TNF inhibitors were used for 24 weeks, but the long‐term risk is not known.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 22, 2018 Category: Rheumatology Authors: Takahisa Suzuki, Shoichi Fukui, Kunihiko Umekita, Junya Miyamoto, Masataka Umeda, Ayako Nishino, Akitomo Okada, Tomohiro Koga, Shin ‐ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Keita Fujikawa, Toshiyuki Aramaki, Akinari Mizokami, Naoki M Tags: Brief Report Source Type: research
Involvement of X chromosome short arm in autoimmune diseases: comment on the article by Sharma et al
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 18, 2018 Category: Rheumatology Authors: Wesley H. Brooks Tags: Letters Source Type: research
Does rheumatoid arthritis cause an obesity paradox? Comment on the article by Sparks et al
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 18, 2018 Category: Rheumatology Authors: Joshua F. Baker, Gail Kerr, Ted R. Mikuls Tags: Letters Source Type: research
Reply
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 18, 2018 Category: Rheumatology Authors: Jeffrey A. Sparks, Elizabeth W. Karlson Tags: Reply Source Type: research
Proteasomal function is impaired in human osteoarthritic chondrocytes and this can contribute to decreased SOX9 and aggrecan
ConclusionDeficient PSMD11, associated with less phosphorylated FOXO4, promotes impaired proteasomal function in OA chondrocytes, dysregulated chondrocytic homeostasis, and decreased levels of SOX9 mRNA, SOX9 protein, and AGC1 mRNA. Chondrocyte proteasomal impairment may be a therapy target for OA.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 18, 2018 Category: Rheumatology Authors: Ramon L Serrano, Liang ‐Yu Chen, Martin K Lotz, Ru Liu‐Bryan, Robert Terkeltaub Tags: Full Length Source Type: research
Evidence for Alternate Modes of B cell Activation Involving Fab Acquired ‐N‐Glycosylations in Antibody Secreting Cells Infiltrating the Labial Salivary Glands of Sjögren's Syndrome Patients
ConclusionOur findings support an alternative mechanism involving V‐region N‐glycosylation for the selection and proliferation of some autoreactive B cells in SS patients.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 18, 2018 Category: Rheumatology Authors: Kristi A. Koelsch, Joshua Cavett, Kenneth Smith, Jacen S. Moore, Sylvain D. Lehoux, Nan Jia, Tim Mather, Syed M. S. Quadri, Astrid Rasmussen, C. Erick Kaufman, David M. Lewis, Lida Radfar, Teresa A. Scordino, Christopher J. Lessard, Biji T. Kurien, Richar Tags: Full Length Source Type: research
Editorial: Tumor Necrosis Factor Antagonists: Killing Two Birds With One Biologic Stone
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 13, 2018 Category: Rheumatology Authors: Joan M. Bathon, Jon T. Giles, Daniel H. Solomon Tags: Editorial Source Type: research
Tumor Necrosis Factor Antagonists: Killing Two Birds With One Biologic Stone
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 13, 2018 Category: Rheumatology Authors: Joan M. Bathon, Jon T. Giles, Daniel H. Solomon Tags: Editorial Source Type: research
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52 ‐Week Phase 3 Randomized Study Results
ConclusionSB5 was well tolerated over 1 year in patients with RA with comparable efficacy, safety, and immunogenicity to ADA. Switching from ADA to SB5 had no treatment‐emergent issues such as increased adverse events, increased immunogenicity, or loss of efficacy.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 13, 2018 Category: Rheumatology Authors: Michael E. Weinblatt, Asta Baranauskaite, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz ‐Rosiak, Inyoung Baek, Jeehoon Ghil Tags: Full Length Source Type: research
Reply to “Necessity for interrupted time series to analyze the effects of propoxyphene withdrawal from the market and further health outcome trend estimates”
This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - February 13, 2018 Category: Rheumatology Authors: Fenglong Xie, Lang Chen, Huifeng Yun, Jeffrey R Curtis Tags: Reply to Letter to the Editor Source Type: research
